The β3‐adrenoreceptor agonist mirabegron for the treatment of combined pre‐ and post‐capillary pulmonary hypertension: new pathway or dead end?

Abstract

This article refers to '𝛃3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE-HF): a double blind, placebo-controlled, randomized clinical trial' by A. García-Álvarez et al., published in this issue on pages 373-385.